Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/123144
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Relaxin as a therapeutic target for the cardiovascular complications of diabetes |
Author: | Ng, H.H. Leo, C.H. Parry, L.J. Ritchie, R.H. |
Citation: | Frontiers in Pharmacology, 2018; 9(MAY):501-1-501-10 |
Publisher: | Frontiers Media |
Issue Date: | 2018 |
ISSN: | 1663-9812 1663-9812 |
Statement of Responsibility: | Hooi Hooi Ng, Chen Huei Leo, Laura J. Parry and Rebecca H. Ritchie |
Abstract: | Cardiovascular complications are the major cause of mortality in patients with diabetes. This is closely associated with both macrovascular and microvascular complications of diabetes, which lead to organ injuries in diabetic patients. Previous studies have consistently demonstrated the beneficial effects of relaxin treatment for protection of the vasculature, with evidence of antioxidant and anti-remodeling actions. Relaxin enhances nitric oxide, prostacyclin and endothelium-derived hyperpolarization (EDH)- type-mediated relaxation in various vascular beds. These effects of relaxin on the systemic vasculature, coupled with its cardiac actions, reduce pulmonary capillary wedge pressure and pulmonary artery pressure. This results in an overall decrease in systemic and pulmonary vascular resistance in heart failure patients. The anti-fibrotic actions of relaxin are well established, a desirable property in the context of diabetes. Further, relaxin ameliorates diabetic wound healing, with accelerated angiogenesis and vasculogenesis. Relaxin-mediated stimulation of vascular endothelial growth factor (VEGF) and stromal cell-derived factor 1-a, as well as regulation of metalloproteinase expression, ameliorates cardiovascular fibrosis in diabetic mice. In the heart, relaxin is a cardioprotective molecule in several experimental animal models, exerting antifibrotic, anti-hypertrophy and anti-apoptotic effects in diabetic pathologies. Collectively, these studies provide a foundation to propose the therapeutic potential for relaxin as an adjunctive agent in the prevention or treatment of diabetes-induced cardiovascular complications. This review provides a comprehensive overview of the beneficial effects of relaxin, and identifies its therapeutic possibilities for alleviating diabetes-related cardiovascular injury. |
Keywords: | Relaxin; diabetes; vasculopathy; endothelial dysfunction; remodeling; cardiomyopathy |
Description: | Published: 15 May 2018 |
Rights: | Copyright © 2018 Ng, Leo, Parry and Ritchie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
DOI: | 10.3389/fphar.2018.00501 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1059960 |
Published version: | http://dx.doi.org/10.3389/fphar.2018.00501 |
Appears in Collections: | Aurora harvest 4 Pharmacology publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_123144.pdf | Published version | 532.08 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.